AbbVie Inc. $ABBV Stock Position Lessened by MassMutual Private Wealth & Trust FSB

Key Points

• MassMutual Private Wealth & Trust FSB reduced its AbbVie position by 5.2% in the third quarter, selling 8,510 shares and retaining 155,837 shares valued at approximately $40.8 million. Institutional investors and hedge funds collectively own 70.23% of AbbVie.
• AbbVie reported quarterly earnings of $3.65 per share, exceeding estimates of $3.61, while revenue rose 10.2% year over year to $16.99 billion. The company also declared a quarterly dividend of $1.73 per share, representing a 2.6% annualized yield.
• Analyst sentiment remains favorable, with AbbVie carrying a “Moderate Buy” consensus rating and an average price target of $272.39; Wolfe Research and BMO Capital Markets raised their targets to $300. Shares recently opened at $263.27, near the 12-month high of $269.39.

MassMutual Private Wealth & Trust FSB decreased its holdings in AbbVie Inc. (NYSE:ABBV - Free Report) by 5.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 155,837 shares of the company's stock after selling 8,510 shares during the quarter. AbbVie comprises 1.0% of MassMutual Private Wealth & Trust FSB's investment portfolio, making the stock its 22nd largest holding. MassMutual Private Wealth & Trust FSB's holdings in AbbVie were worth $40,765,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Corient Private Wealth LP acquired a new position in AbbVie in the second quarter valued at $559,736,000. Legal & General Group Plc purchased a new position in shares of AbbVie during the second quarter worth about $2,905,952,000. Capital World Investors grew its holdings in shares of AbbVie by 106.3% during the fourth quarter. Capital World Investors now owns 13,071,444 shares of the company's stock worth $2,986,777,000 after buying an additional 6,736,161 shares during the last quarter. Jupiter Topco LLC acquired a new position in AbbVie in the 2nd quarter valued at about $1,560,354,000. Finally, Cardano Risk Management B.V. raised its stake in AbbVie by 914.6% during the 4th quarter. Cardano Risk Management B.V. now owns 5,444,930 shares of the company's stock valued at $1,244,112,000 after acquiring an additional 4,908,260 shares during the last quarter. Institutional investors and hedge funds own 70.23% of the company's stock.

Insider Activity

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the transaction, the executive vice president owned 74,430 shares in the company, valued at $18,607,500. This trade represents a 30.53% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.06% of the stock is owned by corporate insiders.

AbbVie Price Performance

ABBV opened at $263.27 on Monday. The business has a 50 day simple moving average of $257.87 and a 200-day simple moving average of $234.68. The stock has a market capitalization of $465.14 billion, a P/E ratio of 74.37, a P/E/G ratio of 1.19 and a beta of 0.24. AbbVie Inc. has a 12 month low of $190.75 and a 12 month high of $269.39.

AbbVie (NYSE:ABBV - Get Free Report) last announced its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, topping analysts' consensus estimates of $3.61 by $0.04. The firm had revenue of $16.99 billion for the quarter, compared to analyst estimates of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.AbbVie's quarterly revenue was up 10.2% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Research analysts anticipate that AbbVie Inc. will post 14.05 EPS for the current year.

AbbVie Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be paid a dividend of $1.73 per share. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.6%. AbbVie's dividend payout ratio is 195.48%.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on ABBV. Weiss Ratings raised AbbVie from a "hold (c)" rating to a "buy (b-)" rating in a research report on Tuesday, August 4th. Wall Street Zen cut AbbVie from a "strong-buy" rating to a "buy" rating in a research note on Sunday, July 5th. Wolfe Research upgraded shares of AbbVie from a "peer perform" rating to an "outperform" rating and lifted their price objective for the company from $235.00 to $300.00 in a research report on Thursday, August 13th. Oppenheimer lifted their price objective on shares of AbbVie from $244.00 to $258.00 and gave the company a "neutral" rating in a research report on Monday, August 3rd. Finally, BMO Capital Markets upped their price objective on shares of AbbVie from $258.00 to $300.00 and gave the stock an "outperform" rating in a research report on Monday, July 13th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and six have issued a Hold rating to the company's stock. Based on data from MarketBeat, AbbVie has an average rating of "Moderate Buy" and an average target price of $272.39.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: The FDA approved AbbVie’s new Parkinson’s disease pill, Juvmo, with a commercial launch targeted for October 2026. The product expands AbbVie’s neuroscience portfolio and could provide another source of growth beyond its immunology franchise. FDA approves AbbVie’s Juvmo for Parkinson’s Disease
• Positive Sentiment: Analysts’ consensus price target was reportedly raised 10.06% to MX$5,190.34, reinforcing bullish expectations. Separately, one analysis estimated that ABBV could be 41% undervalued following the Juvmo approval, although valuation models are inherently subjective. AbbVie consensus price target increased
• Positive Sentiment: New long-term data showed AbbVie’s RINVOQ continued to improve facial and total-body repigmentation in non-segmental vitiligo patients through week 76. The findings may strengthen RINVOQ’s commercial opportunity, though safety, reimbursement and competitive considerations remain important. AbbVie presents long-term RINVOQ data
• Neutral Sentiment: AbbVie will report third-quarter 2026 results before the market opens on October 30. The event gives investors a near-term catalyst to assess Skyrizi and Rinvoq growth, the post-Humira transition and management’s outlook. AbbVie third-quarter 2026 earnings conference call
• Neutral Sentiment: An update on an ongoing Greek clinical study is evaluating venetoclax in acute myeloid leukemia. The study remains an incremental pipeline development rather than a definitive efficacy or regulatory catalyst. AbbVie’s Venetoclax AML study update
• Negative Sentiment: AbbVie agreed to participate in a U.S. government pilot testing a new prescription-drug rebate system. While participation could improve relations with policymakers and potentially expand access, changes to rebates and pricing may create uncertainty around net drug prices and margins. AbbVie joins U.S. government pilot to test drug discount rebates
• Negative Sentiment: Despite strong recent performance, investors continue to weigh AbbVie’s elevated valuation, Humira revenue erosion and competition affecting its growth outlook. These risks could limit further upside even as newer products gain traction.

AbbVie Company Profile

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women's health.

The company's products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.